Cargando…

Novel prognostic markers within the CD44‐stromal ligand network in pancreatic cancer

The dense stroma in pancreatic cancer tumours is rich in secreted extracellular matrix proteins and proteoglycans. Secreted hyaluronan, osteopontin and type IV collagen sustain oncogenic signalling by interactions with CD44s and its variant isoform CD44v6 on cancer cell membranes. Although well esta...

Descripción completa

Detalles Bibliográficos
Autores principales: Franklin, Oskar, Billing, Ola, Öhlund, Daniel, Berglund, Anette, Herdenberg, Carl, Wang, Wanzhong, Hellman, Urban, Sund, Malin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463864/
https://www.ncbi.nlm.nih.gov/pubmed/30456933
http://dx.doi.org/10.1002/cjp2.122
_version_ 1783410818968190976
author Franklin, Oskar
Billing, Ola
Öhlund, Daniel
Berglund, Anette
Herdenberg, Carl
Wang, Wanzhong
Hellman, Urban
Sund, Malin
author_facet Franklin, Oskar
Billing, Ola
Öhlund, Daniel
Berglund, Anette
Herdenberg, Carl
Wang, Wanzhong
Hellman, Urban
Sund, Malin
author_sort Franklin, Oskar
collection PubMed
description The dense stroma in pancreatic cancer tumours is rich in secreted extracellular matrix proteins and proteoglycans. Secreted hyaluronan, osteopontin and type IV collagen sustain oncogenic signalling by interactions with CD44s and its variant isoform CD44v6 on cancer cell membranes. Although well established in animal and in vitro models, this oncogenic CD44‐stromal ligand network is less explored in human cancer. Here, we use a pancreatic cancer tissue microarray from 69 primary tumours and 37 metastatic lymph nodes and demonstrate that high tumour cell expression of CD44s and, surprisingly, low stromal deposition of osteopontin correlate with poor survival independent of established prognostic factors for pancreatic cancer. High stromal expression of hyaluronan was a universal trait of both primary tumours and metastatic lymph nodes. However, hyaluronan species of different molecular mass are known to function differently in pancreatic cancer biology and immunohistochemistry cannot distinguish between them. Using gas‐phase electrophoretic molecular mobility analysis, we uncover a shift towards high molecular mass hyaluronan in pancreatic cancer tissue compared to normal pancreas and at a transcriptional level, we find that hyaluronan synthesising HAS2 correlates positively with CD44. The resulting prediction that high molecular mass hyaluronan would then correlate with poor survival in pancreatic cancer was confirmed in serum samples, where we demonstrate that hyaluronan >27 kDa measured before surgery is an independent predictor of postoperative survival. Our findings confirm the prognostic value of CD44 tissue expression and highlight osteopontin tissue expression and serum high molecular mass hyaluronan as novel prognostic markers in pancreatic cancer.
format Online
Article
Text
id pubmed-6463864
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-64638642019-04-22 Novel prognostic markers within the CD44‐stromal ligand network in pancreatic cancer Franklin, Oskar Billing, Ola Öhlund, Daniel Berglund, Anette Herdenberg, Carl Wang, Wanzhong Hellman, Urban Sund, Malin J Pathol Clin Res Original Articles The dense stroma in pancreatic cancer tumours is rich in secreted extracellular matrix proteins and proteoglycans. Secreted hyaluronan, osteopontin and type IV collagen sustain oncogenic signalling by interactions with CD44s and its variant isoform CD44v6 on cancer cell membranes. Although well established in animal and in vitro models, this oncogenic CD44‐stromal ligand network is less explored in human cancer. Here, we use a pancreatic cancer tissue microarray from 69 primary tumours and 37 metastatic lymph nodes and demonstrate that high tumour cell expression of CD44s and, surprisingly, low stromal deposition of osteopontin correlate with poor survival independent of established prognostic factors for pancreatic cancer. High stromal expression of hyaluronan was a universal trait of both primary tumours and metastatic lymph nodes. However, hyaluronan species of different molecular mass are known to function differently in pancreatic cancer biology and immunohistochemistry cannot distinguish between them. Using gas‐phase electrophoretic molecular mobility analysis, we uncover a shift towards high molecular mass hyaluronan in pancreatic cancer tissue compared to normal pancreas and at a transcriptional level, we find that hyaluronan synthesising HAS2 correlates positively with CD44. The resulting prediction that high molecular mass hyaluronan would then correlate with poor survival in pancreatic cancer was confirmed in serum samples, where we demonstrate that hyaluronan >27 kDa measured before surgery is an independent predictor of postoperative survival. Our findings confirm the prognostic value of CD44 tissue expression and highlight osteopontin tissue expression and serum high molecular mass hyaluronan as novel prognostic markers in pancreatic cancer. John Wiley & Sons, Inc. 2018-12-13 /pmc/articles/PMC6463864/ /pubmed/30456933 http://dx.doi.org/10.1002/cjp2.122 Text en © 2018 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Franklin, Oskar
Billing, Ola
Öhlund, Daniel
Berglund, Anette
Herdenberg, Carl
Wang, Wanzhong
Hellman, Urban
Sund, Malin
Novel prognostic markers within the CD44‐stromal ligand network in pancreatic cancer
title Novel prognostic markers within the CD44‐stromal ligand network in pancreatic cancer
title_full Novel prognostic markers within the CD44‐stromal ligand network in pancreatic cancer
title_fullStr Novel prognostic markers within the CD44‐stromal ligand network in pancreatic cancer
title_full_unstemmed Novel prognostic markers within the CD44‐stromal ligand network in pancreatic cancer
title_short Novel prognostic markers within the CD44‐stromal ligand network in pancreatic cancer
title_sort novel prognostic markers within the cd44‐stromal ligand network in pancreatic cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463864/
https://www.ncbi.nlm.nih.gov/pubmed/30456933
http://dx.doi.org/10.1002/cjp2.122
work_keys_str_mv AT franklinoskar novelprognosticmarkerswithinthecd44stromalligandnetworkinpancreaticcancer
AT billingola novelprognosticmarkerswithinthecd44stromalligandnetworkinpancreaticcancer
AT ohlunddaniel novelprognosticmarkerswithinthecd44stromalligandnetworkinpancreaticcancer
AT berglundanette novelprognosticmarkerswithinthecd44stromalligandnetworkinpancreaticcancer
AT herdenbergcarl novelprognosticmarkerswithinthecd44stromalligandnetworkinpancreaticcancer
AT wangwanzhong novelprognosticmarkerswithinthecd44stromalligandnetworkinpancreaticcancer
AT hellmanurban novelprognosticmarkerswithinthecd44stromalligandnetworkinpancreaticcancer
AT sundmalin novelprognosticmarkerswithinthecd44stromalligandnetworkinpancreaticcancer